VisionWave Holdings, Inc.
VWAVWDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
rebamipide 2% ophthalmic suspension
Keratoconjunctivitis Sicca
SHJ002
Corneal Erosion
ACU-4429
Dry Age-related Macular Degeneration
Emixustat
Stargardt Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rebamipide 2% ophthalmic suspension | Phase 3 | Keratoconjunctivitis Sicca | - | - |
SHJ002 | Phase 2 | Corneal Erosion | - | - |
ACU-4429 | Phase 2 | Dry Age-related Macular Degeneration | - | - |
Emixustat | Phase 2 | Stargardt Disease | - | - |
Frequently asked questions
What is in VisionWave Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in VisionWave Holdings, Inc.'s (VWAVW) pipeline across Phase 3, Phase 2. Its lead program is rebamipide 2% ophthalmic suspension (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VisionWave Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VisionWave Holdings, Inc. (VWAVW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VWAVW biotech catalysts?→
Add VWAVW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VisionWave Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.